Tumor-Specific T Cell Activation in Malignant Brain Tumors.
Antigens, Neoplasm
/ immunology
Brain Neoplasms
/ immunology
Cancer Vaccines
/ immunology
Glioblastoma
/ immunology
Humans
Immunotherapy, Adoptive
/ methods
Lymphocyte Activation
Lymphocytes, Tumor-Infiltrating
/ immunology
Precision Medicine
/ methods
T-Lymphocytes, Regulatory
/ immunology
Tumor Escape
Tumor Microenvironment
/ immunology
T cells
glioblastoma
glioma
immunity
immunotherapy
tumor-infiltrating lymphocytes
tumor-specific
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
11
2019
accepted:
27
01
2020
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
20
2
2021
Statut:
epublish
Résumé
Due to their delicate locations as well as aggressive and infiltrative behavior, malignant brain tumors remain a therapeutic challenge. Harnessing the efficacy and specificity of the T-cell response to counteract malignant brain tumor progression and recurrence, represents an attractive treatment option. With the tremendous advances in the current era of immunotherapy, ongoing studies aim to determine the best treatment strategies for mounting a tumor-specific immune response against malignant brain tumors. However, immunosuppression in the local tumor environment, molecular and cellular heterogeneity as well as a lack of suitable targets for tumor-specific vaccination impede the successful implementation of immunotherapeutic treatment strategies in neuro-oncology. In this review, we therefore discuss the role of T cell exhaustion, the genetic and antigenic landscape, potential pitfalls and ongoing efforts to overcome the individual challenges in order to elicit a tumor-specific T cell response.
Identifiants
pubmed: 32117316
doi: 10.3389/fimmu.2020.00205
pmc: PMC7031483
doi:
Substances chimiques
Antigens, Neoplasm
0
Cancer Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
205Informations de copyright
Copyright © 2020 Mohme and Neidert.
Références
J Immunother. 2001 Jul-Aug;24(4):323-33
pubmed: 11565834
Acta Neuropathol. 2017 Aug;134(2):297-316
pubmed: 28332095
Mol Cell Proteomics. 2015 Mar;14(3):658-73
pubmed: 25576301
Cancer Cell. 2018 Apr 9;33(4):581-598
pubmed: 29634946
Nat Rev Neurosci. 2011 Aug 03;12(9):495-508
pubmed: 21811295
Neuro Oncol. 2017 Apr 1;19(4):546-557
pubmed: 28201779
Cancer Immunol Immunother. 2011 Sep;60(9):1299-307
pubmed: 21626030
Clin Cancer Res. 2018 Jun 1;24(11):2559-2573
pubmed: 29500275
Science. 2015 May 15;348(6236):803-8
pubmed: 25837513
Mol Cell Proteomics. 2007 Jan;6(1):102-13
pubmed: 17074750
Clin Cancer Res. 2011 Jul 1;17(13):4296-308
pubmed: 21478334
Oncoimmunology. 2016 Jun 16;5(11):e1196310
pubmed: 27999734
J Immunother Cancer. 2016 May 17;4:28
pubmed: 27190629
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Annu Rev Immunol. 2015;33:169-200
pubmed: 25493333
Clin Cancer Res. 2017 Jan 1;23(1):124-136
pubmed: 27358487
J Clin Neurosci. 2010 Nov;17(11):1381-5
pubmed: 20727764
Clin Cancer Res. 2018 Sep 1;24(17):4175-4186
pubmed: 29437767
J Neuroimmunol. 2013 Nov 15;264(1-2):71-83
pubmed: 24045166
Oncotarget. 2015 Mar 10;6(7):4704-16
pubmed: 25609200
J Exp Med. 2008 Mar 17;205(3):595-610
pubmed: 18299400
Leukemia. 2016 Apr;30(4):1003-4
pubmed: 27049048
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Nature. 2019 Jan;565(7738):234-239
pubmed: 30568305
Oncoimmunology. 2018 Feb 14;7(4):e1316438
pubmed: 29632711
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Cancer Immunol Immunother. 2004 Mar;53(3):187-95
pubmed: 14758508
J Clin Oncol. 2016 Jul 1;34(19):2206-11
pubmed: 27001570
Nat Genet. 2016 Jul;48(7):768-76
pubmed: 27270107
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
J Immunol. 2017 Oct 15;199(8):2639-2651
pubmed: 28904123
Clin Cancer Res. 2006 Dec 15;12(24):7306-15
pubmed: 17189402
Int J Cancer. 2017 Nov 1;141(9):1891-1900
pubmed: 28681455
Clin Cancer Res. 2019 Oct 1;25(19):5799-5807
pubmed: 31320597
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Annu Rev Immunol. 2003;21:659-84
pubmed: 12615890
PLoS One. 2017 Sep 7;12(9):e0181538
pubmed: 28880903
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Immunology. 2018 Jul;154(3):331-345
pubmed: 29658117
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):566-575
pubmed: 17255279
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16013-8
pubmed: 16247014
Int J Cancer. 2007 Jul 1;121(1):95-105
pubmed: 17315190
Nat Biotechnol. 2013 Oct;31(10):880-2
pubmed: 24104749
Brain. 2012 Apr;135(Pt 4):1042-54
pubmed: 22418738
Clin Cancer Res. 2013 Jun 15;19(12):3165-75
pubmed: 23613317
Neuro Oncol. 2016 Feb;18(2):195-205
pubmed: 26323609
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75
pubmed: 25548167
Int J Biochem Cell Biol. 2016 Dec;81(Pt A):1-9
pubmed: 27644153
Neuro Oncol. 2015 Jun;17(6):801-9
pubmed: 25618892
J Neurooncol. 2007 Jan;81(2):139-48
pubmed: 17004103
Cancer Immunol Immunother. 2015 Apr;64(4):419-27
pubmed: 25555571
Neuro Oncol. 2015 Aug;17(8):1064-75
pubmed: 25355681
Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951
pubmed: 29093164
Oncoimmunology. 2018 May 24;7(9):e1462430
pubmed: 30228931
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
Oncoimmunology. 2017 Mar 3;6(4):e1295903
pubmed: 28507806
Neurooncol Pract. 2019 Dec;6(6):424-427
pubmed: 31832212
J Immunol. 2013 Nov 1;191(9):4880-8
pubmed: 24078694
Cancer Immunol Res. 2019 Sep;7(9):1401-1411
pubmed: 31266783
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Blood Cancer J. 2016 Apr 08;6:e411
pubmed: 27058226
Nat Commun. 2016 Aug 12;7:12157
pubmed: 27515585
Clin Cancer Res. 2018 Sep 1;24(17):4187-4200
pubmed: 29444930
PLoS One. 2012;7(4):e32614
pubmed: 22485134
Cancer Discov. 2017 Mar;7(3):264-276
pubmed: 28031159
Clin Cancer Res. 2012 Nov 1;18(21):5949-60
pubmed: 22966020
Cancer Res. 2016 Oct 1;76(19):5671-5682
pubmed: 27530322
Cancer Immunol Immunother. 2013 Jan;62(1):125-35
pubmed: 22847020
Oncoimmunology. 2017 Nov 27;7(3):e1398877
pubmed: 29399402
Acta Neuropathol. 2018 Jun;135(6):923-938
pubmed: 29557506
Nature. 2017 Mar 30;543(7647):723-727
pubmed: 28329770
Clin Cancer Res. 2008 Aug 15;14(16):5166-72
pubmed: 18698034
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Immunogenetics. 1999 Nov;50(3-4):213-9
pubmed: 10602881
Clin Cancer Res. 2012 Nov 15;18(22):6110-21
pubmed: 22932670
Oncoimmunology. 2015 Jun 5;4(9):e1036211
pubmed: 26405601
Neuro Oncol. 2012 May;14(5):584-95
pubmed: 22406925
Cancer Treat Rev. 2014 Mar;40(2):248-58
pubmed: 24064197
Nat Med. 2013 Jun;19(6):739-46
pubmed: 23624599
Oncotarget. 2016 Feb 2;7(5):5110-7
pubmed: 26819371
Blood. 2015 Sep 3;126(10):1203-13
pubmed: 26138685
J Immunol. 2017 Nov 1;199(9):3360-3368
pubmed: 28978689
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Immunogenetics. 1995;41(4):178-228
pubmed: 7890324
J Immunother. 2004 May-Jun;27(3):220-6
pubmed: 15076139
Cancer Discov. 2014 Aug;4(8):956-71
pubmed: 24893890
Nat Commun. 2016 Nov 21;7:13404
pubmed: 27869121
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Oncotarget. 2016 Aug 16;7(33):52900-52911
pubmed: 27174915
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Nat Genet. 2017 Apr;49(4):594-599
pubmed: 28263318
Mol Cancer. 2006 Dec 02;5:67
pubmed: 17140455
Nature. 2012 Jan 29;482(7384):226-31
pubmed: 22286061
J Exp Med. 2016 Dec 12;213(13):2835-2840
pubmed: 27903604
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Neuro Oncol. 2017 Aug 1;19(8):1047-1057
pubmed: 28371827
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
J Immunother. 2003 Jul-Aug;26(4):301-12
pubmed: 12843792
Cancer Res. 2004 Jul 15;64(14):4980-6
pubmed: 15256472
Mol Cell Proteomics. 2018 Nov;17(11):2132-2145
pubmed: 30072578
CNS Drugs. 2017 Sep;31(9):723-735
pubmed: 28791656
Clin Cancer Res. 2002 Sep;8(9):2851-5
pubmed: 12231526
J Neurooncol. 2013 Feb;111(3):285-94
pubmed: 23263746
Neoplasia. 2002 Sep-Oct;4(5):388-99
pubmed: 12192597
Clin Cancer Res. 2017 Nov 1;23(21):6650-6660
pubmed: 28751450
Mol Cell Proteomics. 2016 Sep;15(9):3058-70
pubmed: 27412690
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Nat Rev Neurol. 2015 Sep;11(9):504-14
pubmed: 26260659
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254